These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
220 related items for PubMed ID: 19836645
41. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Janus N, Launay-Vacher V, Karie S, Clement O, Ledneva E, Frances C, Choukroun G, Deray G. Eur J Radiol; 2010 Feb; 73(2):357-9. PubMed ID: 19128909 [Abstract] [Full Text] [Related]
44. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Idée JM, Port M, Dencausse A, Lancelot E, Corot C. Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600 [Abstract] [Full Text] [Related]
45. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate. Kadiyala D, Roer DA, Perazella MA. Am J Kidney Dis; 2009 Jan; 53(1):133-7. PubMed ID: 19022548 [Abstract] [Full Text] [Related]
46. Nephrogenic systemic fibrosis: what internists need to know. Darwish T, Wood B. Mo Med; 2009 Jan; 106(5):373-6. PubMed ID: 19902721 [Abstract] [Full Text] [Related]
49. [Nephrogenic systemic fibrosis]. Adar T, Rubinger D, Lalazar G, Levi L, Mizrahi M, Bogot RN. Harefuah; 2008 Oct; 147(10):801-3, 837. PubMed ID: 19039911 [Abstract] [Full Text] [Related]
50. Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis. Marckmann P, Nielsen AH, Sloth JJ. Nephrol Dial Transplant; 2008 Oct; 23(10):3280-2. PubMed ID: 18436563 [Abstract] [Full Text] [Related]
55. Nephrogenic systemic fibrosis developed after recovery from acute renal failure: gadolinium as a possible aetiological factor. Lu CF, Hsiao CH, Tjiu JW. J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):339-40. PubMed ID: 18573157 [No Abstract] [Full Text] [Related]
56. Current status of gadolinium toxicity in patients with kidney disease. Perazella MA. Clin J Am Soc Nephrol; 2009 Feb; 4(2):461-9. PubMed ID: 19201920 [Abstract] [Full Text] [Related]
57. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of the literature. Introcaso CE, Hivnor C, Cowper S, Werth VP. Int J Dermatol; 2007 May; 46(5):447-52. PubMed ID: 17472669 [Abstract] [Full Text] [Related]
59. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Cuffy MC, Singh M, Formica R, Simmons E, Abu Alfa AK, Carlson K, Girardi M, Cowper SE, Kulkarni S. Nephrol Dial Transplant; 2011 Mar; 26(3):1099-101. PubMed ID: 21079195 [Abstract] [Full Text] [Related]
60. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Idée JM, Port M, Medina C, Lancelot E, Fayoux E, Ballet S, Corot C. Toxicology; 2008 Jun 27; 248(2-3):77-88. PubMed ID: 18440117 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]